

Eric Bartee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8039694/publications.pdf>

Version: 2024-02-01

49
papers

1,960
citations

304602

22
h-index

434063

31
g-index

50
all docs

50
docs citations

50
times ranked

2577
citing authors

#	ARTICLE	IF	CITATIONS
1	Downregulation of Major Histocompatibility Complex Class I by Human Ubiquitin Ligases Related to Viral Immune Evasion Proteins. <i>Journal of Virology</i> , 2004, 78, 1109-1120.	1.5	275
2	Quantitative Membrane Proteomics Reveals New Cellular Targets of Viral Immune Modulators. <i>PLoS Pathogens</i> , 2006, 2, e107.	2.1	194
3	TEB4 is a C4HC3 RING finger-containing ubiquitin ligase of the endoplasmic reticulum. <i>Biochemical Journal</i> , 2005, 388, 647-655.	1.7	147
4	Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes. <i>European Journal of Immunology</i> , 2008, 38, 1225-1230.	1.6	135
5	Cytokine determinants of viral tropism. <i>Nature Reviews Immunology</i> , 2009, 9, 645-655.	10.6	121
6	The PHD/LAP-Domain Protein M153R of Myxomavirus Is a Ubiquitin Ligase That Induces the Rapid Internalization and Lysosomal Destruction of CD4. <i>Journal of Virology</i> , 2003, 77, 1427-1440.	1.5	120
7	Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy. <i>Cancer Research</i> , 2017, 77, 2952-2963.	0.4	86
8	RIG-I Mediates the Co-Induction of Tumor Necrosis Factor and Type I Interferon Elicited by Myxoma Virus in Primary Human Macrophages. <i>PLoS Pathogens</i> , 2008, 4, e1000099.	2.1	81
9	The Addition of Tumor Necrosis Factor plus Beta Interferon Induces a Novel Synergistic Antiviral State against Poxviruses in Primary Human Fibroblasts. <i>Journal of Virology</i> , 2009, 83, 498-511.	1.5	77
10	Immune evasion by a novel family of viral PHD/LAP-finger proteins of gamma-2 herpesviruses and poxviruses. <i>Virus Research</i> , 2002, 88, 55-69.	1.1	76
11	Membrane-Associated RING-CH Proteins Associate with Bap31 and Target CD81 and CD44 to Lysosomes. <i>PLoS ONE</i> , 2010, 5, e15132.	1.1	74
12	Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines. <i>Frontiers in Immunology</i> , 2019, 10, 263.	2.2	69
13	Selective Purging of Human Multiple Myeloma Cells from Autologous Stem Cell Transplantation Grafts using Oncolytic Myxoma Virus. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1540-1551.	2.0	56
14	The Poxviral RING Protein p28 Is a Ubiquitin Ligase That Targets Ubiquitin to Viral Replication Factories. <i>Journal of Virology</i> , 2005, 79, 597-601.	1.5	54
15	Tumor necrosis factor and interferon: cytokines in harmony. <i>Current Opinion in Microbiology</i> , 2008, 11, 378-383.	2.3	52
16	Cytokine synergy: An underappreciated contributor to innate anti-viral immunity. <i>Cytokine</i> , 2013, 63, 237-240.	1.4	47
17	Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon- γ . <i>Cytokine</i> , 2009, 47, 199-205.	1.4	46
18	Oncolytic Virotherapy for Hematological Malignancies. <i>Advances in Virology</i> , 2012, 2012, 1-8.	0.5	31

#	ARTICLE	IF	CITATIONS
19	Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells. <i>Virology</i> , 2010, 401, 266-279.	1.1	26
20	Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16032.	2.0	25
21	Syncytia Formation in Oncolytic Virotherapy. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 131-139.	2.0	25
22	Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 203-212.	0.2	23
23	Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro. <i>Leukemia Research</i> , 2012, 36, 619-624.	0.4	20
24	Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme. <i>Oncolytic Virotherapy</i> , 2018, Volume 7, 107-116.	6.0	15
25	Virotherapy Using Myxoma Virus Prevents Lethal Graft-versus-Host Disease following Xeno-Transplantation with Primary Human Hematopoietic Stem Cells. <i>PLoS ONE</i> , 2012, 7, e43298.	1.1	14
26	The use of oncolytic virotherapy in the neoadjuvant setting. , 2022, 10, e004462.		11
27	Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma. <i>Oncolytic Virotherapy</i> , 2015, 4, 1.	6.0	10
28	Potential of oncolytic viruses in the treatment of multiple myeloma. <i>Oncolytic Virotherapy</i> , 2018, Volume 7, 1-12.	6.0	9
29	Interleukin-23 receptor signaling by interleukin-39 potentiates T cell pathogenicity in acute graft-versus-host disease. <i>American Journal of Transplantation</i> , 2021, 21, 3538-3549.	2.6	9
30	In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade. <i>Experimental Hematology and Oncology</i> , 2017, 6, 15.	2.0	7
31	B cells imprint adoptively transferred CD8 ⁺ T cells with enhanced tumor immunity. , 2022, 10, e003078.		7
32	Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication. , 2020, 8, e000804.		5
33	Reduced cellular binding affinity has profoundly different impacts on the spread of distinct poxviruses. <i>PLoS ONE</i> , 2020, 15, e0231977.	1.1	5
34	Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapy. , 2019, 7, 11.		4
35	Refinement and Successful Implementation of a Scoring System for Myxomatosis in a Susceptible Rabbit (<i>Oryctolagus cuniculus</i>) Model. <i>Comparative Medicine</i> , 2018, 68, 280-285.	0.4	2
36	TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy. , 2022, 10, e004770.		2

#	ARTICLE	IF	CITATIONS
37	<p>Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus</p>. Oncolytic Virotherapy, 2019, Volume 8, 57-69.	6.0	0
38	Decreasing the Susceptibility of Malignant Cells to Infection Does Not Impact the Overall Efficacy of Myxoma Virus-Based Oncolytic Virotherapy. Molecular Therapy - Oncolytics, 2020, 19, 323-331.	2.0	0
39	Potential Role of IL-39 in the Development of Cvh. Blood, 2019, 134, 3206-3206.	0.6	0
40	Title is missing!. , 2020, 15, e0231977.		0
41	Title is missing!. , 2020, 15, e0231977.		0
42	Title is missing!. , 2020, 15, e0231977.		0
43	Title is missing!. , 2020, 15, e0231977.		0
44	Title is missing!. , 2020, 15, e0231977.		0
45	Title is missing!. , 2020, 15, e0231977.		0
46	Title is missing!. , 2020, 15, e0231977.		0
47	Title is missing!. , 2020, 15, e0231977.		0
48	Title is missing!. , 2020, 15, e0231977.		0
49	Title is missing!. , 2020, 15, e0231977.		0